No. 18-692

Mylan Pharmaceuticals Inc., et al. v. UCB, Inc., et al.

Lower Court: Federal Circuit
Docketed: 2018-11-27
Status: Denied
Type: Paid
Amici (3)Response Waived
Tags: 35-usc-103 double-patenting federal-circuit graham-factors graham-v-john-deere invention-disclosure lead-compound-test obviousness patent-eligibility patent-law patent-law-doctrine-of-double-patenting patent-validity prior-art
Key Terms:
Arbitration Antitrust Patent JusticiabilityDoctri
Latest Conference: 2019-02-15
Question Presented (AI Summary)

Whether a patentee may obtain a second patent on the same invention actually covered by a former patent to the same patentee

Question Presented (from Petition)

QUESTIONS PRESENTED 1. This Court has long held that “no patent can issue for an invention actually covered by a former patent, especially to the same patentee.” Miller v. Eagle Mfg. Co., 151 U.S. 186, 198 (1894). Because what is already known to the public cannot be taken from it, the issuance of a second patent to an obvious portion of a patented invention is precluded. Petitioners respectfully request this Court to clarify: Whether, under this Court’s well-settled precedent, a patentee may obtain a second patent on the same invention actually covered by a former patent to the same patentee. 2. Holding a claimed invention is obvious requires deciding factual questions, such as the scope and content of the prior art, and the differences between the prior art and the claims at issue. 35 U.S.C. § 103; Graham v. John Deere Co. of Kansas City, 383 U.S. 1, 17-18 (1966). This inquiry is flexible, expansive and technology-neutral. § 103; ASR Int7 Co. v. Teleflex Inc., 550 U.S. 398 (2007). The Federal Circuit subverts this principle by applying its own restrictive, technologyspecific threshold test. Petitioners respectfully request this Court to clarify: Whether, under 35 U.S.C. § 103, a patent may be obtained when the differences between the claimed invention and the prior art were obvious to a person having ordinary skill in the art, but—before addressing the Graham factors—a judge decides that an undisputed prior-art reference does not meet the Federal Circuit’s restrictive “lead compound test”.

Docket Entries

2019-02-19
Petition DENIED.
2019-01-09
DISTRIBUTED for Conference of 2/15/2019.
2018-12-27
Brief amicus curiae of Association for Accessible Medicine filed.
2018-12-27
Brief amicus curiae of America’s Health Insurance Plans filed.
2018-12-26
Waiver of right of respondents UCB, Inc., et al. to respond filed.
2018-12-24
Blanket Consent filed by Respondents, Apotex Corp. and Apotex, Inc..
2018-12-21
Brief amici curiae of R Street Institute and Public Knowledge filed.
2018-12-17
Blanket Consent filed by Petitioners, Mylan Pharmaceuticals Inc., et al..
2018-11-21
Petition for a writ of certiorari filed. (Response due December 27, 2018)

Attorneys

America’s Health Insurance Plans
Anna-Rose MathiesonCalifornia Appellate Law Group LLP, Amicus
Anna-Rose MathiesonCalifornia Appellate Law Group LLP, Amicus
Apotex Corp. and Apotex, Inc.
Ian ScottTaft Stettinius & Hollister, LLP, Respondent
Ian ScottTaft Stettinius & Hollister, LLP, Respondent
Association for Accessible Medicine
Richard Jerold HoskinsSchiff Hardin LLP, Amicus
Richard Jerold HoskinsSchiff Hardin LLP, Amicus
Mylan Pharmaceuticals Inc., et al.
David Sidney SteuerWilson, Sonsini, et al., Petitioner
David Sidney SteuerWilson, Sonsini, et al., Petitioner
R Street Institute and Public Knowledge
Charles DuanR Street Institute, Amicus
Charles DuanR Street Institute, Amicus
UCB, Inc., et al.
Adam R. GahtanFenwick & West, LLP, Respondent
Adam R. GahtanFenwick & West, LLP, Respondent